Cushing Syndrome — Screening & Localization

Key Points

• Cushing syndrome is chronic pathologic cortisol excess.
• First exclude exogenous glucocorticoid exposure from oral, injected, inhaled, topical, and supplement sources.
• After endogenous hypercortisolism is confirmed, measure ACTH.
• Use 1-mg overnight dexamethasone suppression and other targeted evaluation to answer specific diagnostic or safety questions rather than ordering broad testing without a plan.
• Escalate urgently for severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism.
• Other major warning findings include rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH and post-treatment adrenal insufficiency, which may emerge after successful cortisol-lowering therapy.
• Medication and procedural choices should be matched to physiology, contraindications, renal/hepatic function, pregnancy status, and interaction risk when relevant.
• Monitor diabetes, blood pressure, potassium, bone health, infection risk, mood, thrombosis risk, and adrenal function.

Algorithm

1. Confirm that the presentation is consistent with Cushing Syndrome — Screening & Localization and identify immediately life-threatening alternatives or complications.
2. Obtain a focused history and examination that define severity, mechanism, relevant comorbidity, prior treatment, and baseline function.
3. Use targeted evaluation such as 1-mg overnight dexamethasone suppression, Late-night salivary cortisol, and other tests only when they can change management.
4. Classify the patient into a treatment pathway based on stability, disease/procedure subtype, organ function, and the presence or absence of escalation findings.
5. Begin the first-line intervention described for Cushing Syndrome — Screening & Localization, using the least complex safe regimen that directly treats the mechanism.
6. Reassess symptoms, vital signs, examination, laboratory or imaging response, and treatment toxicity after the first clinically meaningful interval.
7. Stop routine progression and escalate care for severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism, rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH, or post-treatment adrenal insufficiency, which may emerge after successful cortisol-lowering therapy.
8. At discharge or transition, document the final diagnosis, remaining uncertainty, medication/procedure plan, follow-up timing, prevention strategy, and explicit return precautions.

Clinical Synopsis & Reasoning

Cushing syndrome is chronic pathologic cortisol excess. Because obesity, diabetes, hypertension, depression, and menstrual irregularity are common in the general population, testing is most appropriate when multiple progressive or discriminatory features are present—such as easy bruising, facial plethora, proximal myopathy, wide violaceous striae, unexplained osteoporosis, adrenal incidentaloma, or unusually early/severe metabolic disease.

First exclude exogenous glucocorticoid exposure from oral, injected, inhaled, topical, and supplement sources. Initial screening uses one of three validated approaches: a 1-mg overnight dexamethasone suppression test, late-night salivary cortisol (usually repeated), or 24-hour urinary free cortisol (usually at least two collections). Abnormal results should be confirmed with another appropriate test and interpreted for pseudo-Cushing states, medications affecting dexamethasone metabolism, altered cortisol-binding globulin, shift work, renal impairment, and alcohol use.

The practical diagnostic task is to decide what must be established immediately, what can be clarified after stabilization, and which finding would change the working diagnosis. Useful evaluation elements include 1-mg overnight dexamethasone suppression, Late-night salivary cortisol, 24-hour urinary free cortisol, ACTH. Each test should answer a defined question rather than be ordered reflexively. Serial examination is especially important when early results can be normal or when treatment itself changes the physiology being measured.

Endocrine disorders are frequently recognized through patterns across several laboratory values rather than an isolated abnormal number. Interpretation should reflect feedback physiology, medication effects, kidney function, pregnancy status, and acute illness. For Cushing Syndrome — Screening & Localization, the clinician should explicitly separate expected findings from escalation findings such as severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism, rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH, or post-treatment adrenal insufficiency, which may emerge after successful cortisol-lowering therapy.

Treatment Strategy & Disposition

After endogenous hypercortisolism is confirmed, measure ACTH. Suppressed ACTH points to an adrenal source and adrenal imaging; normal/high ACTH suggests pituitary or ectopic ACTH and directs pituitary MRI and other source evaluation. Inferior petrosal sinus sampling is used when ACTH-dependent disease remains uncertain, not as a first screening test. Surgery is preferred when a resectable source is identified. Medical options such as osilodrostat, metyrapone, ketoconazole/levoketoconazole, pasireotide, cabergoline, or mifepristone are selected according to source, urgency, comorbidity, and pregnancy potential.

Monitor diabetes, blood pressure, potassium, bone health, infection risk, mood, thrombosis risk, and adrenal function. Clinical recovery lags behind biochemical control.

Treatment should be reassessed after the first meaningful intervention rather than allowed to continue automatically. Relevant medications or therapeutic agents in this topic include Osilodrostat, Metyrapone, Ketoconazole/levoketoconazole, Mifepristone. Their usefulness depends on the indication, patient physiology, and contraindications shown in the sections below. If the response is poorer than expected, revisit the diagnosis, treatment delivery, adherence or access, procedure success when relevant, and the possibility of a complication.

Treatment can change electrolytes and hormone levels quickly, so the safest plan specifies what will be rechecked, when it will be rechecked, and which result should stop or change therapy. Long-term endocrine care should address complications, medication adherence, fertility or pregnancy issues when relevant, and patient self-management.

Epidemiology / Risk Factors

• Cushing Syndrome — Screening & Localization illustrates how endocrine disease often emerges from a physiologic pattern across symptoms, feedback hormones, electrolytes, and organ function.
• Medication effects, pregnancy, kidney function, and acute illness can change both laboratory interpretation and treatment safety.
• Because endocrine therapy can shift physiology over hours to weeks, planned laboratory reassessment is part of treatment rather than an optional follow-up step.

Investigations

Cushing Diagnostic Sequence

Pharmacology

Prognosis / Complications

• Outcome in Cushing Syndrome — Screening & Localization depends on baseline severity, underlying mechanism, comorbidity, speed of appropriate treatment, and whether major complications develop.
• Patients who respond as expected still need follow-up focused on recurrence prevention, treatment adverse effects, and restoration of function or physiologic stability.
• The appearance of severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism or rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH changes prognosis and should prompt a higher-acuity reassessment rather than routine outpatient progression.
• A durable plan is one that the patient can follow outside the clinical setting and that includes clear thresholds for returning to care.

Patient Education / Counseling

• Explain the diagnosis of Cushing Syndrome — Screening & Localization in plain language, including what is known, what remains uncertain, and what the immediate treatment is intended to accomplish.
• Review how the patient should take or use the recommended therapy and what common adverse effects or practical barriers to expect.
• Explain that worsening symptoms are not always a normal part of recovery and give specific return precautions for severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism.
• Also seek prompt care for rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH or post-treatment adrenal insufficiency, which may emerge after successful cortisol-lowering therapy.
• Discuss prevention or risk reduction relevant to the condition, including medication adherence, follow-up testing, rehabilitation, vaccination, sexual/partner management, or lifestyle factors as appropriate.
• Use teach-back at discharge so the patient or caregiver can state the treatment plan, follow-up timing, and reasons to return.

Notes

The main practical error in Cushing Syndrome — Screening & Localization is to reduce the topic to a memorized list without linking each action to a clinical purpose. A safer approach identifies the decision point, chooses the test or intervention that changes that decision, and then reassesses whether the patient is moving in the expected direction. Findings such as severe infection, uncontrolled hypertension, heart failure, hypokalemia, psychosis, or thromboembolism due to marked hypercortisolism, rapidly progressive ACTH-dependent syndrome suggesting ectopic ACTH, and post-treatment adrenal insufficiency, which may emerge after successful cortisol-lowering therapy should move the patient out of a routine pathway and into higher-acuity diagnostic or specialty assessment.

Documentation should make the reasoning reproducible. Record the baseline state, the key evidence supporting the diagnosis, major alternatives that were addressed, treatment actually delivered, response, and the follow-up responsibility. This is particularly important when multiple clinicians will share care or when a procedure, high-risk medication, evolving laboratory abnormality, or time-sensitive infection/vascular syndrome is involved. Once the patient is stable, the remaining work is prevention: address modifiable risk, treatment access, adherence, functional recovery, and the specific complication most likely to cause return to care.

References

1. Endocrine Society - Clinical Practice Guidelines — Link
2. American Diabetes Association - Standards of Care in Diabetes — Link